Novartis files for Japanese approval of COPD combo QVA149
This article was originally published in Scrip
Executive Summary
Hot on the heels of the recent marketing authorization application in Europe, Novartis has filed for the Japanese approval of the combination therapy QVA149 as a once-daily maintenance treatment for chronic obstructive pulmonary disease (COPD).